Why Nuvation Bio Inc.’s (NUVB) Stock Is Up 8.84%
As of Wednesday, August 19, Nuvation Bio Inc.’s NUVB share price has surged by 8.84%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Commentary & Analysis
Why Nuvation Bio Inc.’s (NUVB) Stock Is Up 7.94%
As of Friday, August 07, Nuvation Bio Inc.’s NUVB share price has surged by 7.94%, which has investors questioning if this is right time to sell.Michael Rose
Is Nuvation Bio Inc. (NUVB) Overvalued?
We dive into why Nuvation Bio Inc. (NUVB) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Tudor Pop
Why Nuvation Bio Inc.’s (NUVB) Stock Is Up 5.11%
As of Tuesday, August 04, Nuvation Bio Inc.’s NUVB share price has surged by 5.11%, which has investors questioning if this is right time to sell.Michael Rose
Why Nuvation Bio Inc.’s (NUVB) Stock Is Down 5.15%
As of Friday, July 31, Nuvation Bio Inc.’s NUVB share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | NUVB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,398.2 | $618.0 | 56% |
|
| Shares Out (Mil) | 348.8 | 44.8 | 84% |
|
| Institutional Ownership | 75.1% | 85.3% | 45% |
|
| Float (Mil) | 263.6 | 47.4 | 78% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 6,468 | 390 | 94% |
|
| Price Change (52-week) |
153.9% | 68.6% | 95% |
|
| Growth | NUVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (37.5%) | (1.6%) | 10% |
|
| EPS (5yr) | (7.0%) | 14.9% | 24 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 7.1% | (14.9%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.090) | ($0.290) | ($0.015) | |
| Month Ago EPS | ($0.110) | ($0.280) | ($0.060) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.110) | ($0.280) | ($0.060) | |
| Year/Year Chg | (50.0%) | (51.6%) | (101.7%) | |
| Financials | NUVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $170 | $291 | 31% |
|
| Net Income (TTM) (Mil) | ($150) | ($11) | 9% |
|
| EPS (TTM) | ($0.439) | ($0.700) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($121) | ($6) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $11 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $396 | $6 | 56% |
|
| Enterprise Value (Q1) (Mil) | na | $450 | na |
|
| Valuation | NUVB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.36 | 2.78 | 89% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NUVB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 88.2% | 67.0% | 93% |
|
| Net Margin | (88.2%) | (2.3%) | 8% |
|
| ROA | (21.5%) | (22.4%) | 20% |
|
| ROE | (47.8%) | (20.2%) | 16% |
|
| Liabilities to Assets | 65.9% | 32.2% | 61% |
|
| F-Score | 4 | 3 | 34% |
|
Nuvation Bio Inc. did not pass any screens on 8/20/2026.
